Brane Grambozov
Salzburg, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Toxicity management in thoracic chemoradioimmunotherapy: pirfenidone for low grade pneumonitis and lung fibrosis.
Journal: Chinese clinical oncology
Published: June 11, 2026
Computed tomography monitoring of small lung nodules: finding the right balance.
Journal: Translational cancer research
Published: March 03, 2026
Toxicity management in thoracic chemoradioimmunotherapy: pirfenidone for low grade pneumonitis and lung fibrosis.
Journal: Chinese clinical oncology
Published: January 28, 2026
Lung cancer survivorship: natural language processing for automated abstraction of follow-up computed tomography indication.
Journal: Translational lung cancer research
Published: November 24, 2025
MLR and dMLR Predict Locoregional Control and Progression-Free Survival in Unresectable NSCLC Stage III Patients: Results from the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).
Journal: Journal of clinical medicine
Published: October 17, 2025
Durvalumab Is Associated with Prolonged Progression-Free Survival, While Concomitant Chemoradiotherapy May Improve Both Locoregional and Local Control in Elderly Patients with Unresectable NSCLC Stage III: Subanalysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).
Journal: Medical sciences (Basel, Switzerland)
Published: October 03, 2025
Delta Changes in [18F]FDG PET/CT Parameters Can Prognosticate Clinical Outcomes in Recurrent NSCLC Patients Who Have Undergone Reirradiation-Chemoimmunotherapy.
Journal: Biomedicines
Published: June 23, 2025
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).
Journal: Journal of clinical medicine
Published: December 15, 2024
Immediate start of durvalumab after chemoradiotherapy in unresectable non-small cell lung cancer UICC stage III: early results from the TORG1937/DATE study.
Journal: Journal of thoracic disease
Published: September 29, 2024
Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR).
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: February 20, 2024
Stereotactic body radiation therapy (SBRT) in patients with hepatocellular cancer-a narrative review and expert opinion.
Journal: Journal of gastrointestinal oncology
Published: September 14, 2023
Last Updated: 09/26/2026